SNT Biotech operates the first fully integrated at-home HPV self-collection solution for health plans, reaching the members who never make it to a clinic and closing the cervical cancer screening gap at the source.
U.S. women who are behind on or have never had cervical screening
Of cervical cancers occur in women who are unscreened or under-screened
Average kit return rate for a Medicaid health plan, well above program norms
Cervical cancer is nearly always preventable when precancer is caught early
Together with Waters Corporation, SNT Biotech brings a clinically validated HPV solution to health plans end to end: member outreach, self-collection kits, processing in our own accredited lab, and audit-ready reporting, all from one partner.
A pelvic exam and a clinic visit are real barriers, especially in underserved communities. When women fall behind on screening, cervical cancer is caught later, when it is harder and costlier to treat. At-home HPV self-collection removes the barrier, so a simple kit at home replaces a visit that may never happen.
Every part of the cervical screening journey, engagement through reporting, runs on one platform and our own lab. Nothing is stitched together, and nothing falls through the cracks.
Samples are processed in our own high-complexity CLIA and COLA accredited laboratory, not a rented network, so quality and turnaround stay in our hands.
A 50-state contracted physician network and nationwide fulfillment let us run your program wherever your members are.
Built to scale from a pilot to your entire eligible population, with the infrastructure and real-time reporting an enterprise program demands.
Engagement, kitting, lab, and reporting under one roof, so your data stays clean and nothing falls between vendors.
FDA-approved BD Onclarity with extended genotyping, for richer risk stratification than HPV 16 and 18 alone.
Multilingual, at-home access reaches the members who are hardest to engage and most at risk.
The FDA-approved BD Onclarity HPV assay detects 14 high-risk genotypes and, with extended genotyping, reports 6 individually (16, 18, 31, 45, 51, 52) plus pooled groups, for richer risk stratification than HPV 16 and 18 alone.
NCQA has confirmed that HPV testing closes the Cervical Cancer Screening gap whether the sample is collected at home or in a clinic, so a self-collected result counts for your measure.
Member outreach, self-collection kits, laboratory processing in our own accredited lab, and audit-ready reporting, delivered as a single solution.
BD Onclarity is a trademark of Becton, Dickinson and Company. Trademarked product references are subject to partner communications review prior to external publication.
The FDA cleared at-home HPV self-collection, making it possible to screen without a clinic visit or pelvic exam.
Federal coverage requirements take effect, expanding access to at-home HPV screening for members nationwide.
SNT Biotech is onboarding national and regional health plans, with programs live for measurement year 2026.
Our mission is to bring screening to the people who need it most, and catch disease early enough to change the outcome.
Yes. The kit uses the FDA-approved BD Onclarity HPV assay, and NCQA has confirmed that HPV testing closes the Cervical Cancer Screening gap whether the sample is collected at home or in a clinic.
No. Members collect their own sample at home with a simple self-collection kit and clear instructions, which is exactly what removes the barrier for so many overdue women.
It detects 14 high-risk HPV genotypes and, with extended genotyping, reports 6 of them individually (16, 18, 31, 45, 51, 52) along with pooled genotype groups.
In our own high-complexity, CLIA-certified and COLA-accredited laboratory, so quality, turnaround, and reporting stay in our hands.
Medicaid, Medicare Advantage, and commercial health plans, with a particular focus on reaching underserved communities.
See how quickly SNT Biotech can bring at-home HPV self-collection to your members.